Good afternoon and welcome to today’s conference call for Omeros Corporation. At this time, all participants are in a listen-only mode. After the company's remarks, we will conduct a question-and-answer session. Please be advised that this call is being recorded at the company's request and a replay will be available on the company's website for one week from today. Before I turn over the call, management has asked me to remind you that some of the statements made on the call today will be forward-looking statements. These statements are based on management’s beliefs and expectations as of today only and are subject to change. All forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially. Please refer to the risk factors section of the company’s quarterly reports filed with the SEC earlier today for a discussion of these risks and uncertainties. Now, I would like to turn the call over to Dr. Greg Demopulos, Chairman and CEO of Omeros.

Thank you and good afternoon everyone. With me today is Mike Jacobsen, our Vice President of Finance and Chief Accounting Officer. I’ll start today’s call by providing a corporate update including a discussion of the recent news on Omidria, after which Mike will provide an overview of our third quarter financial results. We have reserved time for Q&A after the financial overview. Our first commercial product Omidria was approved by the FDA on May 30 for use during cataract surgery or intraocular lens replacement. As many of you know Omidria is the only FDA approved product where intraocular administration that maintains pupil diameter by preventing intraoperative miosis or pupil construction and reduces post-operative pain providing consistent and predictable management of these problems for ophthalmic surgeons and their patients. As we announced last week, we’ve received transitional pass through reimbursement status for Omidria from the Center for Medicare and Medicaid Services or CMS. This will be effective as of January 1, 2015. We are obviously pleased with this outcome and we appreciate CMS’s collaborative approach and their final decision. As you may know the pass-through program was initiated by Medicare in 2001 to ensure that important new technologies can be appropriately utilized and evaluated by healthcare providers. Pass-through is important for Omidria because ambulatory surgery centers and other outpatient facilities will be able to bill Medicare and other insurance providers for Omidria separately from the cost of the procedure. We expect pass-through reimbursement to remain in effect for a period of two to three years after which time; CMS will make a new reimbursement determination. We believe that pass-through status should accelerate adoption of the product across cataract and other intraocular lens procedures and should streamline the billing and reimbursement process for providers that use Omidria. The need to maintain pupil…

Thanks, Greg and hello everyone. For the quarter ended September 30, 2014, we reported a net loss of $18.3 million or $0.54 per share which includes non-cash expenses of $2.5 million or $0.07 per share. This compares to a net loss of $13.9 million or $0.46 per share for the same period in 2013, which included non-cash expenses of $3.4 million or $0.11 per share. Operating expenses for this quarter were $17.3 million compared to $13.6 million one year ago. The increase was primarily related to preparing for the US commercial launch of Omidria which we are planning for early in 2015 and to cost associated with our Phase 2 clinical trials evaluating OMS824 in Huntington’s and OMS721 in TMAs. NIH grant revenue for the current quarter was $214,000 compared to $196,000 for the same period a year ago. At September 30, 2014, we had cash and cash equivalents and short-term investments of $21.8 million. As Greg discussed earlier, we plan to launch Omidria in the US in early 2015. Accordingly, we do not project any product revenue in the fourth quarter of this year. In addition, we expect our operating expenses will increase over the current quarter run rate primarily due to increased activities related to the US commercial launch and the continued development of our product candidates. We also expect that our non-cash expenses will increase. That concludes our financial update let’s turn the call back to the operator for the question and answer session.

(Operator Instructions) Our first question is from Jason Kolbert of Maxim Group. You may begin.

Hi guys this is Cecily calling in for Jason Kolbert. Congrats on the pass-through pricing. How might that affect the CMS bundling?

I am Sorry, can you – how will that affect the CMS bundling?

Bundling, yes.

For specifically, cataract surgery?

Yes.

Yes, it’s actually, reimbursed outside of the bundle for cataract and refractive lens surgery. So it is outside of that bundle. So it should not affect and will not affect that during the pass-through period that bundle.

Got it. Thank you.

Thank you. Our next question is from Yatin Suneja of Cowen and Company. You may begin. Yatin Suneja – Cowen and Company: Hi, guys, thank you for taking my question and congrats on all the progress. Greg, you mentioned that you are going to hire now 40 reps. could you talk about the – do you think that these 40 reps would be enough to effectively target all the physicians and centers in the US and maybe talk about how many centers are there and how many are you planning to target? And then one more question, are you also planning to hire people who will primarily work on long-term reimbursement? Thank you.

Yes, thank you, Yatin. With respect to your first question, remember that we already have 20 reps hired. We are talking about now, and in the process of hiring an additional 20 and as I said earlier, we expect to have those hired, trained and in the field by the end of January which will bring the sales force which is solely dedicated to Omeros and at this point solely dedicated to Omidria to a total of 40 representatives. In terms of the ability of that, that group to access adequately the ophthalmic surgeons who perform cataract and intraocular lens replacement. We are very comfortable with that number. We are targeting first and foremost, high volume cataract surgeons. So certainly expect we are going to be able to do that. We haven’t given specifics numbers yet as to what percentage of sites we expect to be able to detail, but the numbers will be substantial. So we are actually very comfortable with that 40. Your second question with respect to long-term reimbursement. Again, we are thankful and frankly very appreciative of the decision by CMS to provide pass-through reimbursement for Omidria. But as we look to having pass-through begin on January 1, of this coming year 2015, you have to imagine that we are already thinking about what we need to do to obtain really long-term reimbursement for the product. We are looking at multiple approaches there and we’ve been active on that already as you might imagine and we plan to remain very active on that effort throughout the period of transitional pass-through. Yatin Suneja – Cowen and Company: Thank you.

Thank you. Our next question is from Steve Brozak of WBB. You may begin. Steve Brozak – WBB Securities: Hey, congratulations gentlemen. There is one item that you had mentioned before in terms of Omidria’s standard of use which I would assume would be same as standard of care. In comparing what’s currently out there, i.e., compounding and reimbursement for that, what exactly – why exactly would a physician go out there and defy standard of care and what are the financial considerations and also frankly in going up against standard of care, what kind of a business model would anyone think of using versus just simply using Omidria?

It’s a good question Steve and not to parse words here, but I prefer the term standard of use as opposed to standard of care, standard of care is medical, legal implications and I think, I’d prefer standard of use here. But, I think your question is relevant in either case. I mean, look, it is a very good question where we are optimistic about the potential utilization of Omidria. We are not overconfident about it, but we are optimistic. In answer to your question directly, I mean, we frankly could not have scripted a better scenario than the one into which we are launching. You have a situation where currently surgeons ophthalmic surgeons who perform these procedures are trying in many cases, trying unsuccessfully to access compounded products, anything they can get their hands on to dilate the pupil to cape the pupil open during the surgical procedure. As you know, with the Drug Quality and Security Act that was passed in November of last year that has just made access to compounded products and FDA’s view on compounded products much more restrictive. So, surgeons currently are having a difficult time accessing those products and remember that those products really don’t do what Omidria does. So Epinephrine for example dilates the pupil only, remember that Omidria not only dilates, but more importantly in cataract surgery it prevents miosis or pupil constriction that’s really the key. There is no other product that does what Omidria does and so here we have a product that is FDA approved has a well understood, well known safety profile and that’s in comparison to compounded products that are difficult to access really aren’t as effective as Omidria and don’t carry that same safety profile. And then when you layer on top of that that those compounded products need to be purchased out of the bundle payment for cataract surgery and in this case again, thanks to the decision by CMS. Omidria will be reimbursed. So when you put all of that together, I think, it’s difficult for me to give you a really good answer as to why a surgeon would opt for a compounded product over Omidria. But again, we’ll have to see how the launch proceeds and how sales ramp following launch. Steve Brozak – WBB Securities: Well, I can only say, I am really, really looking forward to 2015 and the launch given everything you just said. Congratulations again. Terrific job.

Thank you, Steve. We are looking forward to it as well. It actually is an exciting time for us. Steve Brozak – WBB Securities: Thank you.

Thank you. Our next question is from Serge Belanger of Needham and Company. You may begin. Serge Belanger – Needham and Company: Hey, good afternoon. Couple questions on Omidria I guess for Greg. What prompted the doubling of the sales force at this point? And it sounds like the first 20 sales reps already being calling surgeons; will the next 20 be calling the same group or a different group of physicians and surgeons?

Hi, Serge. Again, good question. But let me start with some of the questions that you had near the end and I’ll work back to the front. Yes, you are correct that the 20 sales reps we already have begun making calls on ophthalmic surgeons and their staffs so their facilities in August. We are hiring another 20. This was actually a decision that was made a while ago, but pulling the trigger on that was held really until we had clarity from CMS on whether or not there would be reimbursement for Omidria. Now I could make the argument either way that had we not received reimbursement, we should have gone ahead with an additional 20 reps and really pushed hard, where in that case, payment for the product would have come out of the bundle. I can also make the other argument that certainly, with reimbursement; we want to make sure that we are really crossing that starting line with a fully functional hard driving sales force. I think, coming back to the decision, it was really one of just holding until we had clarity. Given that we now have that clarity, we did go ahead and pulled the trigger on those additional 20 sales reps. We expect clearly that those 20 sales reps will be able to spread out our reach with our sales force and increase the number of ophthalmic surgeons facilities, ophthalmic surgery staff that our sales force will be able to access. Serge Belanger – Needham and Company: Okay, and then, one more. Just going forward, any plans on providing guidance, I know it’s probably too early in the game to provide revenue guidance, but at least in operating expenses to get an idea of what we should expect for, I guess, both R&D and SG&A going forward in 2015 and 2016?

That’s again a very question, Serge and the direct answer to that is, yes, we will be providing guidance with respect to operating expenses and that will be at our next call, which will be early next year. With respect to revenue guidance, we really do not plan to provide guidance, certainly for the first year. We will revisit that decision subsequent to that time, but our plan currently is no, revenue projections or revenue guidance for at least the first year of commercial sales. Let’s just see how things progress. Let’s get our legs underneath us, the sales force, the marketing group; the entire commercial team is sort of champing at the bit to get this going. We are all excited. The objective here is to have as flawless a launch as possible. That’s been our focus and I think the team has really done a tremendous job to make that objective a reality. Serge Belanger – Needham and Company: All right, thank you. Congrats on the progress once again.

Thanks, Serge. I appreciate it.

Thank you. Our next question is from Liana Moussatos from Wedbush Securities. You may begin. Liana Moussatos – Wedbush Securities: Thank you for taking my question. Just a couple questions on OMS 721. You have announced some pre-clinical data on stroke and I am just wondering what the clinical plan is for stroke? And then, when the Phase 2 TMAs data really surrounds year end, what kind of endpoint should we expect to be released with that data?

Hi, Liana. Again, good questions. With respect to your question on stroke, we have not discussed publicly any plans with respect to stroke clinically. One would imagine and certainly would accurate that we are looking at additional indications not only for OMS 721 which is our MAST-2 inhibitor, but also, for MAST-3 inhibition which sits at the top of the alterative pathway. So, which again, we control for a number of alternative pathway-related diseases. So, we are looking at how we expand potential indications across both of those targets, but we’ll update you as we move forward. With respect to the endpoints for the TMA study, I think that you should be looking at those same endpoints that Alexion used for its drug product Soliris in aHUS. So, you are looking at things like that – things that we will be measuring our laboratory measures such as platelet count, haptoglobin, LDH, need for transfusions. These types of things are certainly those which we will be measuring and those that we expect to be sharing with you as we release preliminary data. Liana Moussatos – Wedbush Securities: Thank you very much.

Thanks Liana.

Thank you. Our next question is from Thomas Yip of MLV and Company. You may begin. Thomas Yip – MLV and Company: Hey, guys. Thank you so much for taking my question. Congrats on a great quarter. As we approach the year end and as you guided to the decision by – regarding Omidria in Europe, assuming part of the news that that also provide the news, what this would see through the game plan in Europe?

Thanks, Thomas. Yes, again, in Europe, we do plan to partner that is currently not in our plan to launch and market distribute Omidria independently in Europe. So, we are in discussions around partnering in Europe. We will provide an update as we see appropriate, as you know we really don’t discuss our partnering efforts. But the idea in Europe would be to partner and the timing of launch in Europe as we said, we expect in the first half of 2015. Thomas Yip – MLV and Company: Okay, thanks, that’s good to hear. And just also a quick question about a couple of those assets that you say will – that you plan to move into a clinical study in the upcoming year namely RPD7 do you have pre-clinical data on hand that do you plan to present or announce in the coming months?

Yes, we – that’s a good question as well. Again, remember that, all projections with respect to clinical trials in the coming year are dependent on our ability to move those programs forward and also dependent on sufficient resources to fund those programs. But assuming both of those requirements are met, we do as you know, have preclinical data in – RPD7 inhibitor, actually we have preclinical data in cocaine and alcohol, nicotine, opioid and in binge-eating. We are currently preparing a manuscript that addresses really those preclinical studies as well as the mechanism by which we believe and in fact that we have elucidated around the mechanism of PDE7 inhibition in addiction. So looking specifically at the ventral tegmental area and the nucleus accumbens we have identified what we believe is a mechanism for that activity and we do plan to be putting that out in a publication hopefully later this year, meaning, I’m sorry in 2015. Thomas Yip – MLV and Company: Okay, fantastic. Well, thanks again and we look forward to those new data.

Thank you.

Thank you. Our next question is from Norm Hale of Stifel. You may begin. Norman Hale – Stifel, Nicolaus & Co: Thank you. Greg, in relationship to the GPCR program, obviously you guys have de-orphaned a large number of this GPCR, what is your game plan at the moment in terms of – have you filled out which of these GPCRs you want to keep internally, and those that you want to license out or are you still kind of working with that particular issue?

Yes, thanks Norm. That’s a good question and we – our game plan remains really unchanged there. We have 54 Class-A orphan GPCRs that we have surrogate de-orphanized and the reason I am using that term as opposed to de-orphanization specifically is that, as you know, we are not identifying the endogenous ligand. We are screening compound libraries. So we are finding small molecules out of compound libraries. So this is really surrogate de-orphanization but the effect is that we are able then to identify the primary signaling profile and we believe we are the only ones as you are doing the functionally active compounds. We can identify those primary signaling profiles for those receptors. Now the game plan as I said remains the same. We have 54 of those targets, some of those we will be moving into our development pipeline and we will be developing independently. Our plan still remains to partner a good number of those. And I mentioned, we have initiated medicinal chemistry efforts across a number of those targets. I think I specifically mentioned today GPR17 linked to Remyelination, GPR151 tied to Neuropathic Pain, GPR161 which is – it has a very tight linkage to triple negative breast cancer. Those are ones that certainly we are interested in and we believe others are. Those maybe ones or some subset of those or ones that we could be developing internally. There is a possibility as well that one or more of those could be readily partnered. So, I don’t think we are going into this thinking. This one we are going to independently develop, this one we are going to partner. But we are moving those that we feel are interesting and from a clinical perspective from a biological perspective, but also those which we think we can really add value quickly. Norman Hale – Stifel, Nicolaus & Co: Okay, and from a standpoint of protecting your electro property here, how many patents have you received or patents pending relative to the GPCR?

We have a number of patent applications pending around the GPCR program. We have patents on the screening – proprietary screening method by which we use. With respect to the receptors, the 54 receptors that of which we have found functionally active compounds, those patents are all currently pending. We do remain optimistic that those will begin to issue in the not too distant future. I think that when they do, that will obviously be an important milestone for the program. So, we’ll keep people advised as to our progress there, but really we continue to remain very positive on that program understanding that we have not yet announced any partnership around our GPCR program and I know that that was expected by many earlier, in fact, I’ll tell you is expected – that announcement was expected by us earlier. That has not in any way dampened our enthusiasm or our optimism for the program, and again, we don’t discuss partnering efforts, but we will keep people informed as those things occur. Norman Hale – Stifel, Nicolaus & Co: Great. Okay, second question on OMS 824, my understanding is this particularly product has potential for treatment of schizophrenia, Alzheimer’s disease and Huntington’s disease. Which of those three diseases do you think that has being greatest potential and where has the most potential therapeutic benefit?

Interesting question. Certainly, where we focused is in Huntington’s disease and schizophrenia. Remember that, as you pointed out PDE10 inhibitors hold the promise of improving cognition in these cognitive disorders. Our focus on schizophrenia as you know Pfizer also was in schizophrenia. Interestingly, Pfizer is also now in Huntington’s disease. Schizophrenia requires, in most cases, very large studies and they are costly. We believe we can run some schizophrenia studies or studies in patients with schizophrenia a little more cost effectively, again if we are very smart in how we design the study protocols but our focus on Huntington’s also was really one of capability for a company with our resources. I mean, that’s something, that’s an area that we felt that certainly we could and that we can get after with the kind of resources that Omeros has. With respect to biologically which of these areas really hold the most promise for our PDE10 inhibitor in a way your guess is as good as ours. There currently as you know is no commercial validation of a PDE 10 inhibitor and there is really no clinical validation today. I believe that we and Pfizer are at the leading edge in terms of clinical development of the PDE10 inhibitors. So you know, you are not really or we are not really sure how this is all going to wash out. What we are quite confident in is that, PDE10 is going to prove to be a valuable target for some substantial set of CNS disorders. I think that that’s a belief shared by a number of the large pharmaceutical companies who are similarly pursuing PDE10. We believe, we really do have the premier PDE10 inhibitor tied to the absence of extrapyramidal symptoms with our compound even at high interaction with the PDE7, I am sorry, with the PDE 10 enzyme. So, our confidence remains and we will keep people informed as we further sort out what indication is best for PDE10. Obviously, we are also looking at what other groups are doing. So we are very aware of what Pfizer is doing what other companies are doing with their PDE10 inhibitors. Again, believing that ours has very certain advantages. Norman Hale – Stifel, Nicolaus & Co: Okay, right, my third and final question, relative to MASP-2, – right now is hoping for – and agreed some disease as well and from what I am reading, relative to Alexion Pharmaceutical, they are lot of the analysts are projecting that by 2020 revenues are Soliris could in excess supply billing in per year. Do you guys believe that this company that the product – that your product MASP-2 is potentially safer and it is highly effective in the therapeutic benefits. You discussed just little bit about how you see your product versus Soliris.

Yes, it’s again a good question. I don’t feel so comfortable discussing really, comparisons between our product or any of our products and any other product out there. I can tell you that the – what we believe to be the advantages of a MASP-2 inhibitor over a C5 inhibitor in general. One is, you alluded to it when you said safety, I would refine that a bit just to say that MASP-2 inhibition does not affect the lyric arm of the classical pathway. So the ability to fight infection whereas a C5 inhibitor does by its location in the complement system, its downstream location at the top of terminal cascade does by definition lock the lyric arm of the classical pathway. The other advantage we believe that we will see with OMS721 and I think we’ve demonstrated this in our Phase 1 clinical trial as the ability to deliver OMS721 as a subcutaneous administration. This of course is different than C3 inhibitor, C5 inhibitors, those which are targeting really ubiquitous targets in the human. MAST-2 is much lower in concentration. Native circulating levels of MAST-2 are orders of magnitude lower and therefore it makes an inhibitor of MAST-2 amenable to subcutaneous administration as opposed to other targets which require IV – intravenous infusion. We also believe that with respect to Thrombotic Micro Microangiopathies that the role of MAST-2 in the coagulation cascade. So not just the complement system but also the coagulation cascade really play into its ability to be effective in Thrombotic Micro Microangiopathies because of course, the pathophysiological endpoints is thrombus formation. So, the role of the coagulation system certainly is in play in those diseases, not just the complement system. So, having a target that can affect both the complement system and the coagulation cascade, theoretically would be advantageous and this is again where we think OMS721 certainly has a role. Norman Hale – Stifel, Nicolaus & Co: Very good. Thank you very much. You guys really have some exciting products in the pipeline. I think you have a great company. That’s all for me.

Thank you very much Norm.

Thank you. Our next question is from David Cowan [Ph] of MSL you may begin.

Thanks for having the call today and thank you so much for taking my questions. Congratulations on the CMS again as well. So, Greg, I had three questions for you. The first of which is, have you already begun discussions with potential partners for Europe for Omidria? And then the second question is I noted on international GPCR consortium that was formed with pharma and academia was announced last week. Are you planning to participate in that consortium and my third question was, with such a broad portfolio of opportunities, could you give us an idea of how you are prioritizing your opportunities for 2015?

Right. Hi, David, and then thanks. Let’s take them in order. We have said that we are in discussions around the European partnership at that point I just stop and say that we really don’t discuss routinely our partnering efforts. With respect to the GPCR consortium, yes, I think, that’s very interesting. It clearly underscores the importance of GPCR in drug development and in the pharmaceutical industry. Now, remember that these are really looking at structures of those GPCRs. My expectation is that those aren’t orphans, because as you know, the easiest way to get a crystal structure is to also have a ligand. So, orphans don’t have ligands therefore it’s going to be very difficult for, I would expect that consortium to find crystal structures for orphan GPCRs. Having said that, we are interested given that we have ligands. In assessing and determining crystal structures for our GPCRs or for a subset of our GPCRs. Whether that would require us joining that consortium probably premature, I wouldn’t immediately see a need for us to do that or even perhaps the wisdom in us doing that of course unless it was structured around some broader deal structure with pharmaceutical companies interested specifically in crystal structures or GPCRs or who are part of that consortium. But I am not sure that that consortium really helps us in any way, I mean, what we provide. But I don’t mean this arrogantly at all. I am just- and again I’d want to talk in greater depth with our science team but I currently am not seeing what that consortium brings directly to us and our orphan GPCR effort.

Sounds good.

And then your final question about how we prioritize, we are prioritizing all the time with this many assets we have to prioritize. Clearly, our number one priority for 2015 is the successful launch and ramp of Omidria. I mean, that’s critical. I think that, CMS’s favorable decision for us certainly helps along that path. It is the revenue that we expect to generate with Omidria which we expect really brings substantial value to the ophthalmic community kind of in our minds there really is no question about it. This product is needed and we are delivering it. But, those revenues from that program we are really looking to help drive the development of the rest of our pipeline. So, obviously, that is our number one priority. I think, behind that, there is sort of a cluster of priorities. I think OMS 721 our MAST-2 program certainly is a high priority for us. I mean, as I mentioned in my update, we do expect to be releasing data from the ex vivo pathophysiologic system of aHUS looking at thrombus formation. I think you have those data are positive. I will certainly sleep better with respect to the likelihood of success in our Phase II TMA program. I think, so, let’s see what those data look like, we’ll put those out as they are available, but that certainly would move that program high up the priority list for us.

Pardon me, you still – you did expect that data before year end for 721?

Well, for 721, we said the ex vivo pathophysiologic system data on thrombus formation using 721, that’s in the ex vivo system using serum or sera from aHUS patients both in remission and in the acute phase. Actually, David, we said we’ll have those data at this month.

Excellent.

So we’ll be putting those out this month and the data that we are hoping to have before the end of the year are preliminary data from the Phase 2 TMA study. I do think that, the thrombus formation data assuming those are positive and of course, I am not making any comment as to whether they are or are not positive data. We will release them as we have them available. But for purposes of discussion if they were to be positive, I think that that would presage certainly the outcome in the Phase 2 clinical trial to a good extent. That’s our opinion internally. Whether that’s shared externally, I don’t want to comment, but certainly, that would give us increased confidence. I think then, you’ve got to look at 824 our push is to get that off of the clinical enrollment suspension we are currently on. There we were really somewhat victims of our own success. We continue to try to reach a maximum tolerated dose an MTD. And given the safety profile today of that compound and our need to continue to push in human to try find an MTD, well, you need to get coverage in the animals to be able to do that. So at some point, you start to push to the limit of what animals can tolerate and we may have just reached that point. And so our objective here is to get off of that clinical suspension to review and we did put out in the press release what the FDA asked us to do. We are pretty clear about that. And I think that their requests were not overly onerous. We can take that and we expect to be back on. So, I think, I’ll stop there and just say, clearly, we looked at the priorities, we had just them as data come in and it’s somewhat of a living document for us. Without doubt, our primary priority is the success of Omidria.

Awesome, thanks so much for answering my questions, Greg and congratulations again.

Thank you, David.

Thank you. Our next question is from Austin Hopper of AWH Capital. You may begin. Austin Wiggins Hopper – AWH Capital: Hi, Greg. Thanks for taking my question and congrats on all the progress. Can you just comment about Omidria? And kind of what surgeons are doing today to prevent, I guess, really or address pupil constriction? Are they doing anything pre-operatively or intraoperatively? Thank you.

Sure, sure, Austin. What they are currently doing pre-operatively is pretty standard. They use mydriatic topical drops pre-operatively and then inter-operatively, a lot of physicians in the US are using epinephrine in the bag or in the bottle. Now, there is one approved epinephrine for use in the eye and that is a product trade name is Adrenaline, as you would expect to spell it without the E at the end. That epinephrine it does contain bisulfites. As you know Omidria is preservative and bisulfite free. Bisulfites and preservatives are associated with TASS or Toxic Anterior Segment Syndrome, which is a non-infectious inflammatory condition that can be site threatened. So, in all of these products, epinephrine et cetera as I mentioned earlier, dilate only. It is our product Omidria that can inhibit, prevent miosis, which is really the key in these surgical procedures, right. You dilate, but then you have to maintain that dilation and it’s surgical trauma that causes the release of prostaglandins and from local tissues, those prostaglandins is in fact the sphincter muscle in the eye cause that pupil or that iris to come down and so you really want to inhibit that miosis. That’s what Omidria does and it does what really that can’t be done by either phenylephrine alone or epinephrine alone. So we think that certainly we have a superior product. We have a product that’s FDA approved, as opposed to one that is compounded. And as you know, again, I mentioned I think in response to an earlier question about the Drug Quality and Security Act of November of 2013, clearly, the FDA is clamping down and again our opinion only, we don’t expect that to get better. We expect that frankly to become more restrictive with the passage of time. So, let me stop there and I think that I hope that answered your question. Austin Wiggins Hopper – AWH Capital: Great, thank you.

Thank you.

Thank you. Our next question is from David Lundquist of UBS Financial Services. You may begin. David Lundquist – UBS Financial Services: Hi, Greg, congratulations on all the great progress that you and the team are getting here. You’ve referenced resources a couple times and it seems to beg the question to jump back to the financial aspects that maybe Mike can jump in here too. Obviously, where you were a quarter and where you are now, the understandable burn rate is up a bit. Now that you have these business developments, is there a way you can talk around what the variety of options you have in financing going forward might be?

Sure, David. Thanks for the question. As you know, we really don’t comment on our financing plans. But I can answer that in the general which is our options really are the options that we always have. There is the option of partnering from revenues or revenue partnering. There is the option of additional debt or some debt structure and there is the option of equity financing and those are really the three that are in place and all these remain in place. Certainly, we look at our cash situation. But, I think that if you look historically how we at Omeros have managed that, I think, we’ve – I think tended to manage that pretty well. We have a total of slightly less than 34 million outstanding shares as a company that is now commercial or just about to become commercial with sales revenue. So – and that I would expect is really on the low end of the spectrum in terms of outstanding shares a our company of our development stage. So, I think that – and again, I am not trying to side-step your question. David Lundquist – UBS Financial Services: No, fine.

Yes, within the parameters that we really allow ourselves to talk about these kinds of things. But I think that certainly, we handle these things, I think in a pretty smart way and I wouldn’t see that we would bear from that kind of historical track record. David Lundquist – UBS Financial Services: Super, thanks for taking the question and best of luck downstream. Thanks Greg.

Thanks a lot David.

Thank you. I would now like to turn the conference back over to Dr. Demopulos for closing remarks.

Right, thank you very much operator. I appreciate that and that wraps up our call for today. Again, thanks to all of you for taking the time to listen in. As always, all of us Omeros appreciate your continued interest and your support. As I said a little earlier, this really is an exciting time for Omeros and we’ll keep you updated on our progress toward, not only commercially success of Omidria, but also our efforts to advance all of the products in our pipeline. With that, I’ll just say, have a good afternoon and we look forward to talking with you all again.

Thank you. Ladies and gentlemen, this concludes today’s conference. Thank you for your participation. Have a wonderful day.